Aimovig vs Emgality: Comparing Injectable CGRP Antibodies for Migraine Prevention

Although both drugs target the CGRP pathway, they do so at different molecular points—and this distinction has clinical implications.

Aimovig (erenumab) is a fully human monoclonal antibody that binds to the CGRP receptor. By occupying the receptor, it prevents CGRP and other related peptides from binding and triggering the downstream cascade of vasodilation, neurogenic inflammation, and pain signaling that characterizes migraine attacks. Aimovig is the only anti-CGRP antibody that targets the receptor rather than the ligand.

Emgality (galcanezumab) binds directly to the CGRP ligand—the protein itself—neutralizing it before it can reach and activate the receptor. This approach may theoretically provide more complete CGRP blockade because it eliminates the ligand rather than competing with it at the receptor binding site.

In practice, both approaches are highly effective. There is no definitive evidence that one mechanism is superior. Some patients who don't respond to a receptor-targeting antibody (Aimovig) may respond to a ligand-targeting one (Emgality, Ajovy) and vice versa, suggesting the approaches are not interchangeable for all patients.

Both antibodies demonstrate robust efficacy in large Phase 3 trials:

Aimovig (STRIVE trial, 140mg): Reduced monthly migraine days by 3.7 days versus placebo. The ≥50% responder rate was 50% (vs 26.6% placebo). In chronic migraine (≥15 days/month), Aimovig 140mg reduced MMD by 6.6 days.

Emgality (EVOLVE-1 and EVOLVE-2 trials, 120mg): Reduced MMD by 4.7 days (EVOLVE-1) and 4.3 days (EVOLVE-2) versus placebo. The ≥50% responder rate was 62% (EVOLVE-1) and 59% (EVOLVE-2). In chronic migraine (REGAIN trial), Emgality reduced MMD by 4.8 days.

Cross-trial comparisons suggest Emgality may have a slight efficacy advantage, particularly in episodic migraine. However, without head-to-head trials, definitive superiority claims cannot be made. Both are significantly better than placebo and generally better tolerated than traditional preventives. Real-world evidence suggests patients who fail one anti-CGRP antibody may benefit from switching to another.

Both Aimovig and Emgality are generally well-tolerated with side effect profiles far more favorable than traditional migraine preventives.

Aimovig's notable side effects:

• Injection site reactions: ~6%
• Constipation: ~3% (a unique side effect among anti-CGRP antibodies, likely related to CGRP receptor blockade in the gut)
• Muscle cramps/spasms: ~2%
• Rare reports of hypertension, especially in patients with pre-existing cardiovascular risk

Emgality's notable side effects:

• Injection site reactions: ~18% (higher than Aimovig, including pain, redness, itching)
• Hypersensitivity reactions: ~1% (rash, urticaria, rarely anaphylaxis)
• Constipation is rare (<1%)
• The 240mg loading dose (two injections on day 1) may increase initial side effects

Neither drug is recommended during pregnancy. Both are safe in patients with cardiovascular risk factors, though Aimovig has rare post-marketing reports of hypertension that warrant monitoring. Long-term safety data extends 5+ years for both with reassuring results.